BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chroma Therapeutics to Present at 29th Annual J.P. Morgan Healthcare Conference


1/6/2011 10:39:08 AM

Oxford, 6 January 2011 – Chroma Therapeutics Limited, a clinical-stage biotechnology company committed to the development of novel treatments for haematological disorders and autoimmune/inflammatory diseases, announced today that Ian Nicholson, Chief Executive Officer, will present at the 29th Annual J.P. Morgan Healthcare Conference. Mr. Nicholson’s presentation is scheduled to begin at 08:00 a.m. PST on Tuesday, Jan. 11, 2011 at the Westin St. Francis Hotel in San Francisco.

Mr. Nicholson will discuss Chroma's business strategy and to provide updates on the progress of the company's lead agent, tosedostat, which is being progressed towards a global registration study in relapsed/refractory acute myeloid leukemia, along with its innovative portfolio of first-in-class clinical and preclinical agents utilising its novel macrophage-targeting (ESM) technology.

Enquiries

Chroma Therapeutics Limited Ian Nicholson Chief Executive Officer +44 (0)1235 829120 Richard Bungay Chief Financial Officer

Brunswick Jon Coles +44 (0)20 7404 5959 Justine McIlroy

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Phase4 and The Wellcome Trust. More information about Chroma can be found at www.chromatherapeutics.com.

Valerie Mugridge Executive Assistant

Brunswick Group LLP, 16 Lincoln's Inn Fields, London, WC2A 3ED, United Kingdom Tel +44 (0) 20 7404 5959 Direct +44 (0) 20 7396 5325 www.brunswickgroup.com

- Brunswick is a leading international corporate relations and communications consultancy

- Over 80 Partners worldwide across 16 offices in 11 countries



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES